Clinical trial
Tacrolimus and Sirolimus as Prophylaxis After Allogenic Non-myeloablative…
NCT00282282 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00282282 |
|---|---|
| Title | Tacrolimus and Sirolimus as Prophylaxis After Allogenic Non-myeloablative Peripheral Blood Stem Cell Transplantation |
| Official title | Tacrolimus and Sirolimus as Graft Versus Host Disease Prophylaxis After Allogeneic Non-myeloablative Peripheral Blood Stem Cell Transplantation |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | Brigham and Women's Hospital |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Graft Versus Host Disease, GVHD |
| Intervention type | Drug |
| Interventions | tacrolimus, sirolimus, fludarabine, busulfex |
| Enrollment | 31 |
| Start date | Jan 1, 2006 |
| Primary completion | Jan 1, 2009 |
| Completion | Jul 1, 2009 |
| First posted | Jan 26, 2006 |
| Last update posted | May 12, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: